Related references
Note: Only part of the references are listed.Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Ioanna Gouni-Berthold et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
A phase 2 trial of the efficacy and safety of evinacumab in patients with severe hypertriglyceridemia
R.S. Rosenson et al.
ATHEROSCLEROSIS (2021)
Clinical review on triglycerides
Ulrich Laufs et al.
EUROPEAN HEART JOURNAL (2020)
Nucleic Acid-Based Therapies for Atherosclerosis
Petri Makinen et al.
CURRENT ATHEROSCLEROSIS REPORTS (2020)
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia
Massimiliano Ruscica et al.
PHARMACOLOGICAL RESEARCH (2020)
Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis
Mohammad Zarei et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2020)
Genetics of Hypertriglyceridemia
Jacqueline S. Dron et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans
Jan Boren et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance
Rene C. Adam et al.
JOURNAL OF LIPID RESEARCH (2020)
Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia
Daniel Gaudet et al.
EUROPEAN HEART JOURNAL (2020)
Reversal of severe hypertriglyceridemia with intermittent fasting and a very-low-carbohydrate ketogenic diet: a case series
Subrat Das et al.
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY (2020)
Evinacumab for Homozygous Familial Hypercholesterolemia
Frederick J. Raal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Two-Sample Mendelian Randomization Study of Lipid levels and Ischemic Heart Disease
Su Hyun Lee et al.
KOREAN CIRCULATION JOURNAL (2020)
N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels
Veronica J. Alexander et al.
EUROPEAN HEART JOURNAL (2019)
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
J. L. Witztum et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Lomitapide and Mipomersen-Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis
Dirk J. Blom et al.
CURRENT ATHEROSCLEROSIS REPORTS (2019)
Genetic Determinants of Lipids and Cardiovascular Disease Outcomes A Wide-Angled Mendelian Randomization Investigation
Elias Allara et al.
CIRCULATION-GENOMIC AND PRECISION MEDICINE (2019)
Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol
Yu-Xin Xu et al.
ATHEROSCLEROSIS (2018)
Intestinal Failure and Aberrant Lipid Metabolism in Patients With DGAT1 Deficiency
Jorik M. van Rijn et al.
GASTROENTEROLOGY (2018)
GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics
Aaron D. Springer et al.
NUCLEIC ACID THERAPEUTICS (2018)
After Glybera's withdrawal, what's next for gene therapy?
Melanie Senior
NATURE BIOTECHNOLOGY (2017)
ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia
Daniel Gaudet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
Mark J. Graham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Nonfasting Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis
Simon B. Pedersen et al.
JAMA INTERNAL MEDICINE (2016)
New insights into the pathophysiology of dyslipidemia in type 2 diabetes
Marja-Riitta Taskinen et al.
ATHEROSCLEROSIS (2015)
Alipogene Tiparvovec: A Review of Its Use in Adults with Familial Lipoprotein Lipase Deficiency
Lesley J. Scott
DRUGS (2015)
Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome
Charles Daniel Meyers et al.
LIPIDS IN HEALTH AND DISEASE (2015)
Mendelian randomization of blood lipids for coronary heart disease
Michael V. Holmes et al.
EUROPEAN HEART JOURNAL (2015)
Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review
Kelly L. Stoner et al.
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH (2015)
Genetics and Causality of Triglyceride-Rich Lipoproteins in Atherosclerotic Cardiovascular Disease
Robert S. Rosenson et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Severe Hypertriglyceridemia With Pancreatitis Thirteen Years' Treatment With Lomitapide
Frank M. Sacks et al.
JAMA INTERNAL MEDICINE (2014)
The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management
Robert A. Hegele et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Elevated Remnant Cholesterol Causes Both Low-Grade Inflammation and Ischemic Heart Disease, Whereas Elevated Low-Density Lipoprotein Cholesterol Causes Ischemic Heart Disease Without Inflammation
Anette Varbo et al.
CIRCULATION (2013)
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease
Borge G. Nordestgaard et al.
EUROPEAN HEART JOURNAL (2013)
Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial
D. Gaudet et al.
GENE THERAPY (2013)
Common variants associated with plasma triglycerides and risk for coronary artery disease
Ron Do et al.
NATURE GENETICS (2013)
Postprandial lipemia and cardiovascular disease risk: Interrelationships between dietary, physiological and genetic determinants
Kim G. Jackson et al.
ATHEROSCLEROSIS (2012)
IRF-1 and miRNA126 Modulate VCAM-1 Expression in Response to a High-Fat Meal
Chongxiu Sun et al.
CIRCULATION RESEARCH (2012)
Exome Sequencing, ANGPTL3 Mutations, and Familial Combined Hypolipidemia
Kiran Musunuru et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Angptl3 regulates lipid metabolism in mice
R Koishi et al.
NATURE GENETICS (2002)
Share Paper
